OLMA NASDAQ
Olema Pharmaceuticals, Inc.
1W: -2.9%
1M: -18.2%
3M: -37.1%
YTD: -72.2%
1Y: -12.3%
3Y: -33.5%
5Y: -73.7%
$7.04
+0.42 (+6.34%)
Weekly Expected Move ±7.9%
$5
$6
$6
$7
$7
Credit Risk of going bust: lower than 55% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $616.0M.
Distance to default 5.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 112.1%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Olema Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $660K against a stock market value of $616.0M.
Distance to default 5.59 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $660K (short-term plus half of long-term), stock volatility 112.1%; Altman Z'' 6.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$579.2M
52W Range6.235-36.26
Volume1,987,370
Avg Volume1,295,458
Beta2.01
Dividend—
Analyst Ratings
Company Info
CEOSean Bohen
Employees150
SectorHealthcare
IndustryBiotechnology
IPO Date2020-11-19
Websiteolema.com
780 Brannan Street
San Francisco, CA 94103
US
San Francisco, CA 94103
US
650 243 5555
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Latest News
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 52-Week Low – Time to Sell?
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA
Olema drops after hours on AstraZeneca Etcamah data
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| O'Byrne Jason | A-Award | 650,000 | $10.56 | 2026-09-01 |
| O'Byrne Jason | 0 | — | 2026-08-11 | |
| Harmon Cyrus | S-Sale | 12,500 | $11.71 | 2026-07-24 |
| Harmon Cyrus | S-Sale | 12,500 | $11.58 | 2026-07-23 |
| Hrustanovic Gorjan | A-Award | 29,500 | $9.51 | 2026-06-18 |